Meitav Dash Investments LTD Bristol Myers Squibb CO Transaction History

Meitav Dash Investments LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	BUY	$72.62 - $79.98 $346,833 - $381,984	4,776 New	4,776 $368,000
Q1 2022 May 09, 2022	SELL	$61.48 - $73.72 $283,176 - $339,554	-4,606 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$53.63 - $62.52 $32,446 - $37,824	605 Added 15.12%	4,606 $287,000
Q3 2021 Nov 03, 2021	SELL	$59.17 - $69.31 $1.09 Million - $1.28 Million	-18,474 Reduced 82.2%	4,001 $237,000
Q2 2021 Aug 05, 2021	BUY	$61.91 - $67.42 $1.14 Million - $1.25 Million	18,475 Added 461.88%	22,475 $1.5 Million
Q1 2021 May 06, 2021	SELL	$59.34 - $66.74 $53,406 - $60,065	-900 Reduced 18.37%	4,000 $253,000
Q4 2020 Feb 02, 2021	SELL	$57.74 - $65.43 $40,418 - $45,801	-700 Reduced 12.5%	4,900 $303,000
Q3 2020 Nov 05, 2020	BUY	$57.43 - $63.64 $321,608 - $356,384	5,600 New	5,600 $336,000
Q1 2020 May 11, 2020	SELL	$46.4 - $67.43 $283,040 - $411,323	-6,100 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$49.21 - $64.19 $93,499 - $121,961	1,900 Added 45.24%	6,100 $391,000
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $179,634 - $212,982	4,200 New	4,200 $209,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Meitav Dash Investments LTD, based on Form 13F filings with the SEC.

Stay updated on Meitav Dash Investments LTD with notifications on news.